Alex B. Burgin

Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism.

The mechanism of topoisomerase I poisoning by a camptothecin analog.

Regulation of site-specific recombination by the C-terminus of lambda integrase.

A two-drug model for etoposide action against human topoisomerase IIalpha.

Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex.

Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.

Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues.

Mechanisms of camptothecin resistance by human topoisomerase I mutations.

Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I.

Catalytic residues of the telomere resolvase ResT: a pattern similar to, but distinct from, tyrosine recombinases and type IB topoisomerases.

Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.

DNA ligation catalyzed by human topoisomerase II alpha.

Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1).

Uncoupling the chemical steps of telomere resolution by ResT.

A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Tyrosyl-DNA phosphodiesterase (Tdp1) (3'-phosphotyrosyl DNA phosphodiesterase).

Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.

Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage.

Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.

Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.

A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases.

Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV.

Small molecule allosteric modulators of phosphodiesterase 4.

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Artificial neural networks trained to detect viral and phage structural proteins.

Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets.

Structure and function of a cyanophage-encoded peptide deformylase.

Structural basis for the design of selective phosphodiesterase 4B inhibitors.

Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.

A Maltose-Binding Protein Fusion Construct Yields a Robust Crystallography Platform for MCL1.

Non-helical DNA Triplex Forms a Unique Aptamer Scaffold for High Affinity Recognition of Nerve Growth Factor.